Data: Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
| dc.contributor.author | Şam Özdemir, Merve | |
| dc.contributor.author | Kaya, Nurullah | |
| dc.contributor.author | Savun, Metin | |
| dc.contributor.author | Keskin, Emin Taha | |
| dc.contributor.author | Yüzkan, Sabahattin | |
| dc.contributor.author | Arslan, Fatma Zeynep | |
| dc.contributor.author | Budak, Burcu | |
| dc.contributor.author | Omak, Özgür | |
| dc.contributor.author | Yardımcı, Aytül Hande | |
| dc.contributor.author | Özdemir, Harun | |
| dc.date.accessioned | 2025-10-24T11:32:25Z | |
| dc.date.issued | 2024-01-01 | |
| dc.description.abstract | Abstract Purpose Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate. Methods and Materials While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized. This work investigates the use of mpMRI to describe incidental 18 F-FDG uptake in the prostate.mpMRI included T2-weighted (T2W), dynamic contrast enhancement (DCE), and apparent diffusion coefficient (ADC) sequences. Patients were classified according to PI-RADS (Prostate Imaging Reporting and Data System) version 2.1 by an experienced uroradiologist, and 18 F-FDG-PET was evaluated to determine whether the area of involvement on CT had a counterpart in mpMRI. A biopsy was performed on 30 of the 92 patients. These patients’ maximum standardized uptake values (SUVmax) 6 < and ≥ 6, PS(PSA) density 0.15 < and ≥ 0.15, PSA level, uptake pattern (focal involvement/diffuse involvement), and PI-RADS scores were compared. P < .05 was considered statistically significant. Logistic regression was used to analyze PI-RADS score groups age, PSA, PSA density and SUVmax. Results In the study, 92 patients with incidental 18 F-FDG-PET/CT prostate uptake were examined. Median age was 66, PSA median was 3.6 ng/ml (range: 0-3198 ng/ml). Notably, in 70.6% of cases, PET/CT uptake didn’t correlate with mp-MRI findings. Among PI-RADS 3-4-5 patients (29.3%), there was a correlation. Biopsies in 30 patients revealed 43.3% benign, 56.7% malignant. Significant differences between benign and malignant cases were observed in PSA density, PI-RADS scores, and PSA levels (p < .05), while SUVmax and uptake pattern were not significant. In multivariate logistic regression analysis, PI-RADS score groups were found to be independent risk factors for predicting malignancy. Conclusions Our study showed that incidental 18 F-FDG-PET/CT prostate uptake was detected and that high PSA density values, PI-RADS scores, and PSA values, such as in routine patients, and not PET-CT findings such as SUVmax and uptake pattern, were more predictive of malignancy. | |
| dc.description.uri | https://dx.doi.org/10.6084/m9.figshare.c.7595366.v1 | |
| dc.description.uri | https://dx.doi.org/10.6084/m9.figshare.c.7595366 | |
| dc.identifier.doi | 10.6084/m9.figshare.c.7595366.v1 | |
| dc.identifier.openaire | doi_dedup___::cfc61d4205a87a4c50658cf92803af71 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/31238 | |
| dc.publisher | figshare | |
| dc.rights | OPEN | |
| dc.title | Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT? | |
| dc.type | Collection | |
| dspace.entity.type | Data | |
| local.import.source | OpenAire |
